The idea of p53-based cyclotherapy is that a p53 activator ceases proliferation in normal tissues while leaving the p53-deficient tumor susceptible to the toxicity of S- or M-phase chemotherapeutic poisons [18]. The gene discussed is TP53; the disease is neoplasm.